ACTG GO-AHEAD IS PDL RAY OF SUNSHINE; BIOTECHS GET AUGUST BOUNCE FROM STREET
Executive Summary
Protein Design Lab's Protovir AIDS Clinical Trial Group 266 protocol is set to continue at a higher dose, thanks to a positive recommendation Sept. 3 from the ACTG. FDA, the National Institute of Allergy & Infectious Diseases and participating medical centers will need to concur with the recommendation. Enrollment in the 167-patient trial, which is about half complete, was halted pending approval of the higher dose